Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action

Journal of Lipid Research

Volumn 47, Issue 3, 2006, Pages 537-552

  Clark, Ronald W ^a   Ruggeri, Roger B ^a   Cunningham, David ^a   Bamberger, Mark J ^a  

^a PFIZER INC   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; High density lipoprotein; Lipid transfer

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN RECEPTOR; PROTEIN INHIBITOR; TORCETRAPIB; TRIACYLGLYCEROL;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; INCUBATION TIME; LIPID TRANSPORT; MALE; NONHUMAN; PRIORITY JOURNAL; STOICHIOMETRY; SURFACE PLASMON RESONANCE; TITRIMETRY;

ANIMALS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CHO CELLS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GLYCOPROTEINS; PHOSPHOLIPIDS; QUINOLINES; TIME FACTORS;

EID: 33644775588     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M500349-JLR200     Document Type: Article

References (45)

1. Gordon, T., W. P. Castelli, M. C. Hjorland, W. B. Cannel, and T. R. Dawber. 1977. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62: 707-714.
2. Gordon, D. J., J. L. Probstfield, R. J. Garrison, J. D. Neaton, W. P. Castelli, and J. D. Knoke. 1989. High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79: 8-15.
3. Manninen, V., L. Tenkanen, P. Koskinen, J. K. Huttunen, M. Manttari, O. P. Heinonen, and M. H. Frick. 1992. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation. 85: 37-45.
4. Robins, S. J., D. Collins, J. T. Wittes, V. Papademetriou, P. C. Deedwania, E. J. Schaefer, J. R. McNamara, M. L. Kashyap, J. M. Hershman, L. F. Wexler, et al. 2001. Relation of gemfibrozil treatment and lipid levels with major coronary events. J. Am. Med. Assoc. 285: 1585-1591.
5. Barter, P., J. Kastelein, A. Nunn, R. Hobbs, and Future Forum Editorial Board. 2003. High density lipoproteins (HDLs) and atherosclerosis: the unanswered questions. Atherosclerosis. 168: 195-211.
6. McKenney, J. 2004. New perspectives on the use of niacin in the treatment of lipid disorders. Arch. Intern. Med. 164: 697-705.
7. Goldberg, A., P. Alagona, D. M. Capuzzi, J. Guyton, J. M. Morgan, J. Rodgers, R. Sachson, and P. Samuel. 2000. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am. J. Cardiol. 85: 1100-1105.
8. Barter, P. J., H. B. Brewer, J. Chapman, C. H. Hennekens, and D. J. Rader. 2003. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23: 160-167.
9. Rittershaus, C., D. Miller, L. Thomas, M. Picard, C. Honan, C. Emmett, C. Pettey, H. Adari, R. Hammond, D. Beattie, et al. 2000. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20: 2106-2112.
10. Okamoto, H., F. Yonemouri, K. Wakitani, T. Minowa, K. Maeda, and H. Shinkai. 2000. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406: 203-207.
11. Davidson, M. H., K. Maki, D. Umporowicz, A. Wheeler, C. Rittershaus, and U. Ryan. 2003. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis. 169: 113-120.
12. Grooth, J., J. Kuivenhoven, A. Stalenhoef, J. de Graaf, A. Zwinderman, J. Posma, A. van Tol, and J. Kastelein. 2002. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans. Circulation. 105: 2159-2165.
13. Clark, R. W., T. A. Sutfin, R. B. Ruggeri, A. T. Willauer, E. D. Sugarman, G. Magnus-Aryitev, P. G. Cosgrove, T. M. Sand, R. T. Wester, J. A. Williams, et al. 2004. Raising high density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24: 490-497.
14. Brousseau, M. E., E. J. Schaefer, M. L. Wolfe, L. Bloeden, A. G. Digenio, R. W. Clark, J. Mancuso, and D. J. Rader. 2004. Effects of a potent inhibitor of cholesteryl ester transfer protein on plasma lipoproteins in patients with low HDL cholesterol. N. Engl. J. Med. 350: 1505-1515.
15. Morehouse, L. A., E. D. Sugarman, P. A. Bourassa, and A. J. Milici. 2004. HDL elevation by the CETP inhibitor torcetrapib prevents atherosclerosis in rabbits (Abstract 1168 in American Heart Association Scientific Sessions 2004, New Orleans, LA, November 7-10, 2004.).
16. Ikewaki, K., D. J. Rader, T. Sakamoto, M. Nishiwaki, N. Waikimoto, J. R. Schaefer, T. Ishikawa, T. Fairwell, L. A. Zech, H. Nakamura, et al. 1993. Delayed catabolism of high density lipoprotein apolipoprotein A-I and A-II in human cholesteryl transfer protein deficiency. J. Clin. Invest. 92: 1650-1658.
17. Brousseau, M. E., M. R. Difenderfer, J. S. Millar, C. Nartsupha, B. F. Asztalos, F. K. Welty, M. L. Wolfe, M. Rudling, I. Bjorkhem, B. Angelin, et al. 2005. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. 25: 1-8.
18. Ikewaki, K., M. Nishiwaki, T. Sakamoto, T. Ishikawa, T. Fairwell, L. A. Zech, M. Nagano, H. Nakamura, H. B. Brewer, Jr., and D. J. Rader. 1995. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J. Clin. Invest. 96: 1573-1581.
19. Swenson, T. L., R. W. Brocia, and A. R. Tall. 1988. Plasma cholesteryl ester transfer protein has binding sites for neutral lipids and phospholipids. J. Biol. Chem. 263: 5150-5157.
20. Connolly, D. T., J. McIntyre, D. Heuvelman, E. E. Remsen, R. E. McKinnie, L. Vu, M. Melton, R. Monsell, E. Krul, and K. Glenn. 1996. Physical and kinetic characterization of recombinant cholesteryl ester transfer protein. Biochem. J. 320: 39-47.
21. Barter, P. J., and M. E. Jones. 1980. Kinetic studies of the transfer of esterified cholesterol between human plasma low and high density lipoproteins. J. Lipid Res. 21: 238-249.
22. Epps, D. E., K. A. Greenlee, J. S. Harris, E. W. Thomas, C. K. Castle, J. F. Fisher, R. R. Hozak, C. K. Marschke, G. W. Melchoir, and F. J. Kezdy. 1995. Kinetics and inhibition of lipid exchange catalyzed by plasma cholesteryl ester transfer protein (lipid transfer protein). Biochemistry. 34: 12560-12569.
23. Wang, S., P. Kussie, L. Deng, and A. R. Tall. 1995. Defective binding of neutral lipids by a carboxyl-terminal deletion mutant of cholesteryl ester transfer protein. J. Biol. Chem. 270: 612-618.
24. Bruce, C., L. J. Beamer, and A. R. Tall. 1998. The implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of cholesteryl ester transfer protein. Curr. Opin. Struct. Biol. 8: 426-434.
25. Clark, R. W., J. B. Moberly, and M. J. Bamberger. 1995. Low level quantification of cholesteryl ester transfer protein in plasma subfractions and cell culture media by monoclonal antibody-based immunoassay. J. Lipid Res. 36: 876-889.
26. Rose, H. G., and M. Oklander. 1965. Improved procedure for the extraction of lipids from human erythrocytes. J. Lipid Res. 6: 428-431.
27. Jauhiainen, M., J. Metso, R. Pahlman, S. Blomqvist, A. van Tol, and C. Ehnholm. 1993. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J. Biol. Chem. 268: 4032-4036.
28. Wang, S., L. Deng, R. W. Milne, and A. R. Tall. 1992. Identification of a sequence within the C-terminal 26 amino acids of cholesteryl ester transfer protein responsible for binding a neutralizing monoclonal antibody and necessary for neutral lipid transfer activity. J. Biol. Chem. 267: 17487-17490.
29. Ohnishi, T., S. Yokayama, and A. Yamamoto. 1990. Rapid purification of human plasma lipid transfer proteins. J. Lipid Res. 31: 397-406.
30. Nishida, H. I., H. Arai, and T. Nishida. 1993. Cholesteryl ester transfer mediated by lipid transfer protein as influenced by changes in the charge characteristics of plasma lipoproteins. J. Biol. Chem. 268: 16352-16360.
31. Connolly, D. T., B. J. Witherbee, M. A. Melton, R. C. Durley, M. L. Grapperhaus, B. R. McKinnis, W. F. Vernier, M. A. Babler, J. Shieh, M. E. Smith, et al. 2000. Stereospecific inhibition of CETP by chiral N,N-disubstituted trifluro-3-amino-2-propanols. Biochemistry. 39: 13870-13879.
32. Reinhard, E. J., J. L. Wang, R. C. Durley, Y. M. Fobian, M. L. Grapperhaus, B. S. Hickory, M. A. Massa, M. B. Norton, M. A. Promo, M. B. Tollefson, et al. 2003. Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein. J. Med. Chem. 46: 2152-2168.
33. Connolly, D. T., D. Heuvelman, and K. Glenn. 1996. Inactivation of cholesteryl ester transfer protein by cysteine modification. Biochem. Biophys. Res. Commun. 223: 42-47.
34. Hope, H. R., D. Heuvelman, K. Duffin, C. Smith, J. Zablocki, R. Schilling, S. Hedge, L. Lee, B. Witherbee, M. Baganoff, et al. 2000. Inhibition of cholesteryl ester transfer protein by substituted dithiobisnicotinic acid dimethyl ester: involvement of a critical cysteine. J. Lipid Res. 41: 1604-1614.
35. Clark, R. W., G. Chang, and M. T. Didiuk. 2005. Agents for the inhibition of cholesteryl ester transfer protein (CETP) and prospects for the future treatment of atherosclerosis. Curr. Med. Chem. Immunol. Endocrine Metab. Agents. 5: 339-360.
36. Morton, R. E. 1985. Binding of plasma-derived lipid transfer protein to lipoprotein substrates. J. Biol. Chem. 260: 12593-12599.
37. Bruce, C., W. S. Davidson, P. Kussie, S. Lund-Katz, M. C. Phillips, R. Ghosh, and A. R. Tall. 1995. Molecular determinants of plasma cholesteryl ester transfer protein binding to high density lipoproteins. J. Biol. Chem. 270: 11532-11542.
38. Groener, J. E. M., A. J. Rozen, and D. W. Erkelens. 1984. Cholesteryl ester transfer activity: localization and role in distribution of cholesteryl ester among lipoproteins in man. Atherosclerosis. 50: 261-271.
39. Marcel, Y. L., R. McPherson, M. Hogue, H. Czarnecka, Z. Zawadzki, P. K. Weech, M. E. Whitlock, A. R. Tall, and R. W. Milne. 1990. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipidemic subjects. J. Clin. Invest. 85: 10-17.
40. Cheung, M. C., A. C. Wolf, K. D. Lum, J. H. Tollefson, and J. J. Albers. 1986. Distribution and localization of lecithin:cholesterol acyltransferase and cholesteryl ester transfer activity in A-I-containing lipoproteins. J. Lipid Res. 27: 1135-1144.
41. Speijer, H., J. E. M. Groener, E. van Ramshorst, and A. van Tol. 1991. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis. 90: 159-168.
42. Beamer, L. J., S. F. Carroll, and D. Eisenberg. 1997. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science. 276: 1861-1864.
43. Hesler, C. B., A. R. Tall, T. L. Swenson, P. K. Weech, Y. L. Marcel, and R. W. Milne. 1988. Monoclonal antibodies to the Mr 74,000 cholesteryl ester transfer protein neutralize all the cholesteryl ester and triglyceride transfer activities in human plasma. J. Biol. Chem. 263: 5020-5023.
44. Swenson, T. L., C. B. Hesler, M. Brown, E. Quinet, P. P. Trotta, M. F. Haslanger, F. C. A. Gaeta, Y. L. Marcel, R. W. Milne, and A. R. Tall. 1989. Mechanism of cholesteryl ester transfer protein inhibition by a neutralizing monoclonal antibody and mapping of the monoclonal antibody epitope. J. Biol. Chem. 264: 14318-14326.
45. Wang, S., X. Wang, L. Deng, E. Rassart, R. W. Milne, and A. R. Tall. 1993. Point mutagenesis of carboxyl-terminal amino acids of cholesteryl ester transfer protein. J. Biol. Chem. 268: 1955-1959.